Literature DB >> 24295715

Non-steroidal anti-inflammatory drug modulates oxidative stress and calcium ion levels in the neutrophils of patients with primary dysmenorrhea.

Önder Kaplan1, Mustafa Nazıroğlu, Mehmet Güney, Mehmet Aykur.   

Abstract

Primary dysmenorrhea is a common inflammatory disease with an uncertain pathogenesis, although one consistent finding is increased neutrophil activity. We aimed to investigate the effects of a non-steroidal anti-inflammatory drug (NSAID) on oxidative stress and Ca²⁺ levels in neutrophils from patients with primary dysmenorrhea. Blood samples were obtained for neutrophil isolation from six female patients with primary dysmenorrhea (patients) and six healthy female subjects. The NSAID (diclofenac) was taken daily by the patient group for 6 weeks before a second blood sample was taken. Neutrophils isolated after diclofenac treatment were investigated in three settings: (1) after incubation with verapamil and diltiazem (V+D), (2) after incubation with 2-aminoethoxydiphenyl borate (2-APB), and (3) with neither exposure. Neutrophil lipid peroxidation and stimulated intracellular Ca²⁺ levels were higher in the patients than in the controls, although their levels were reduced after six weeks of treatment with diclofenac. Ca²⁺ levels from neutrophils obtained after diclofenac treatment were further decreased after incubation with V+D or 2-APB, compared with those exposed to neither agent. Neutrophil glutathione peroxidase and total antioxidant status were lower in the patients than in the controls and higher post-treatment with diclofenac. Reduced glutathione levels were similar in the control, patient, and treatment groups. In conclusion, we observed the importance of Ca²⁺ influx into the neutrophils and oxidative stress in the pathogenesis of the patients with primary dysmenorrhea. The NSAID diclofenac appeared to provide a protective effect against oxidative stress and Ca²⁺ entry through modulation of neutrophil VGCC and TRP calcium channels.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  2-APB; 2-aminoethoxydiphenyl borate; Antioxidant; Calcium ion; GSH; GSH-Px; MDA; MPO; N-formyl-l-methionyl-l-leucyl-l-phenylalanine; NSAID; Neutrophil; Oxidative stress; Primary dysmenorrhea; ROS; SOD; V+D; VGCC; fMLP; glutathione peroxidase; malondialdehyde; myeloperoxidase; non-steroidal anti-inflammatory drug; reactive oxygen species; reduced glutathione; superoxide dismutase; verapamil+diltiazem; voltage-gated calcium channels

Mesh:

Substances:

Year:  2013        PMID: 24295715     DOI: 10.1016/j.jri.2013.10.004

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  10 in total

1.  Effectiveness and Safety of Moxibustion Robots on Primary Dysmenorrhea: A Randomized Controlled Pilot Trial.

Authors:  Han-Rui Zhang; Hai-Yan Tu; Yu Wang; Shi-Lin Xia; Guo-You Zhao; Ting Yang; Ying-Kun Li
Journal:  Chin J Integr Med       Date:  2021-04-10       Impact factor: 1.978

2.  Involvement of a neutrophil-mast cell axis in the effects of Piper malacophyllum (C. PESL) C. DC extract and its isolated compounds in a mouse model of dysmenorrhoea.

Authors:  Nara Lins Meira Quintão; Jaqueline Pavesi Reis; Larissa Benvenutti; Roberta Nunes; Fernanda Capitanio Goldoni; Manuela Somensi Cozer; Priscila de Souza; Rita de Cássia Melo Vilhena de Andrade Fonseca da Silva; Jessica Melato; Carlos Rafael Vaz; Juliana Cristina Pereira Whitaker; Flavia Werner Jesuíno; Mariana Couto Costa; Maria Verônica Dávila Pastor; Angela Malheiros; Christiane Meyre-Silva; José Roberto Santin
Journal:  Inflammopharmacology       Date:  2022-07-22       Impact factor: 5.093

3.  Moxibustion for Patients with Primary Dysmenorrhea at Different Intervention Time Points: A Randomized Controlled Trial.

Authors:  Li-Ying Liu; Xiao-Ji Li; Wei Wei; Xiao-Li Guo; Li-Hua Zhu; Fei-Fei Gao; Fan-Rong Liang; Si-Yi Yu; Jie Yang
Journal:  J Pain Res       Date:  2020-10-19       Impact factor: 3.133

4.  The Establishment of a Mouse Model of Recurrent Primary Dysmenorrhea.

Authors:  Fang Hong; Guiyan He; Manqi Zhang; Boyang Yu; Chengzhi Chai
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

5.  Anti-tumor Necrosis Factor Alpha (Infliximab) Attenuates Apoptosis, Oxidative Stress, and Calcium Ion Entry Through Modulation of Cation Channels in Neutrophils of Patients with Ankylosing Spondylitis.

Authors:  Yunus Ugan; Mustafa Nazıroğlu; Mehmet Şahin; Mehmet Aykur
Journal:  J Membr Biol       Date:  2016-03-08       Impact factor: 1.843

6.  Animal study on primary dysmenorrhoea treatment at different administration times.

Authors:  Bao-Chan Pu; Ling Fang; Li-Na Gao; Rui Liu; Ai-Zhu Li
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-02       Impact factor: 2.629

Review 7.  Acupuncture for Primary Dysmenorrhea: A Potential Mechanism from an Anti-Inflammatory Perspective.

Authors:  Wen-Yan Yu; Liang-Xiao Ma; Zhou Zhang; Jie-Dan Mu; Tian-Yi Sun; Yuan Tian; Xu Qian; Yi-Dan Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-03       Impact factor: 2.629

8.  Integrated Serum Pharmacochemistry, Metabolomics, and Network Pharmacology to Reveal the Material Basis and Mechanism of Danggui Shaoyao San in the Treatment of Primary Dysmenorrhea.

Authors:  Hui Xiong; Na Li; Lanqingqing Zhao; Zhe Li; Yongzhou Yu; Xiaoyan Cui; Qi Liu; Chunying Zhao
Journal:  Front Pharmacol       Date:  2022-07-11       Impact factor: 5.988

9.  Increased Incidence of Dysmenorrhea in Women Exposed to Higher Concentrations of NO, NO2, NOx, CO, and PM2.5: A Nationwide Population-Based Study.

Authors:  Shih-Yi Lin; Yu-Cih Yang; Cheng-Chieh Lin; Cherry Yin-Yi Chang; Wu-Huei Hsu; I-Kuan Wang; Chia-Der Lin; Chung-Y Hsu; Chia-Hung Kao
Journal:  Front Public Health       Date:  2021-06-17

Review 10.  Effects of acupoint-stimulation for the treatment of primary dysmenorrhoea compared with NSAIDs: a systematic review and meta-analysis of 19 RCTs.

Authors:  Yang Xu; Wenli Zhao; Te Li; Huaien Bu; Zhimei Zhao; Ye Zhao; Shilin Song
Journal:  BMC Complement Altern Med       Date:  2017-08-31       Impact factor: 3.659

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.